Drug Type Small molecule drug |
Synonyms Miransertib (USAN/INN), Miransertib Mesylate, ARQ 092 + [2] |
Target |
Mechanism Proto-oncogene proteins c-akt inhibitors(Proto-oncogene proteins c-akt inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (EU) |
Molecular FormulaC27H24N6 |
InChIKeyHNFMVVHMKGFCMB-UHFFFAOYSA-N |
CAS Registry1313881-70-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Growth Disorders | Phase 2 | ES | 19 Sep 2019 | |
Proteus Syndrome | Phase 2 | ES | - | 17 Sep 2019 |
PIK3CA-related overgrowth syndrome | Phase 2 | ES | - | 16 May 2017 |
Endometrial Carcinoma | Phase 1 | US | 09 Jun 2015 | |
Endometrial Carcinoma | Phase 1 | US | - | 09 Jun 2015 |
Ovarian Cancer | Phase 1 | US | - | 09 Jun 2015 |
Ovarian Cancer | Phase 1 | US | 09 Jun 2015 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | - | 01 Nov 2011 |
Lymphoma | Phase 1 | US | 01 Nov 2011 | |
Recurrent Lymphoma | Phase 1 | US | - | 01 Nov 2011 |
Phase 1/2 | 50 | (Part A: Miransertib PROS/PS) | qvjiguvyba(dspipyntlr) = zdeuwsgsmj uieofqhibo (uzlfnefvbg, taslaszbuq - hvbqqckdbu) View more | - | 31 Mar 2023 | ||
(Part B: Miransertib PROS (Cohort 1)) | qvjiguvyba(dspipyntlr) = tivkdwygrv uieofqhibo (uzlfnefvbg, ewsahnzxfw - skwjlzhpdi) View more | ||||||
Phase 1/2 | - | yksiaqdaji(fgvbefsjua) = mostly Grade 1 or 2 AEs grerximfgi (ureoyraxug ) View more | Positive | 17 Jun 2019 | |||
Not Applicable | 6 | klidngegmc(rawwlokgif) = 50% reduction (5/6) pxkkzpyfvj (emmmxlomws ) | Positive | 07 Mar 2019 | |||
NCT02476955 (ASCO2017) Manual | Phase 1 | 13 | wmgqsfxgpl(roxuwprvfk) = diarrhea 69%, fatigue 54%, hyperglycemia 31%, maculopapular rash 31%, nausea 23%, mucosal inflammation 23%, anemia 15%, platelet count decreased 15% and hypokalemia 15% qpklmgkaph (kodfhlpcll ) View more | Positive | 05 Jun 2017 | ||
Phase 1 | 22 | zayobyfpeg(iabtvayhxg) = ezczueflre aebxhvbiyk (dzcfarhexo ) | - | 15 Apr 2013 |